{"id":"W2597166480","doi":"10.1016/s0735-1097(17)33542-8","title":"USE OF HIGH-INTENSITY STATIN THERAPY POST-ACUTE CORONARY SYNDROME IN THE ONGOING ODYSSEY OUTCOMES TRIAL OF ALIROCUMAB, A PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 MONOCLONAL ANTIBODY, VERSUS PLACEBO: INTERIM BASELINE DATA","year":2017,"lang":"en","type":"article","venue":"Journal of the American College of Cardiology","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"Canadian VIGOUR Centre; University of Alberta","funders":"","keywords":"Alirocumab; Medicine; PCSK9; Acute coronary syndrome; Kexin; Evolocumab; Statin; Internal medicine; Proprotein convertase; Placebo; Cardiology; Interim analysis; Clinical trial; Cholesterol; Lipoprotein; LDL receptor; Pathology; Myocardial infarction","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001165273,0.0009582936,0.002401149,0.0001819532,0.0003760927,0.001215152,0.0004780017,0.0007913192,0.003566272],"category_scores_gemma":[0.001394823,0.0003691293,0.002285199,0.0001967279,0.0005856804,0.0008797869,0.0004984373,0.002252261,0.0003899717],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005877597,"about_ca_system_score_gemma":0.000791073,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001750547,"about_ca_topic_score_gemma":0.005639836,"domain_scores_codex":[0.9994609,0.0002346558,0.0000391862,0.000087269,0.00005247005,0.0001255254],"domain_scores_gemma":[0.9993399,0.000174104,0.0001514071,0.00006834117,0.00005439578,0.0002118328],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9725385,0.001863615,0.004273736,0.0004664748,0.002987868,0.00003304032,0.00005557233,0.0002905953,0.001425527,0.0001328278,0.0008452086,0.01508688],"study_design_scores_gemma":[0.8575941,0.05118671,0.07821982,0.0001711336,0.007224841,0.00007922443,0.0001386807,0.00133065,0.001172219,0.0006697085,0.002155801,0.00005707742],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9907942,0.004294433,0.0003272383,0.0005631641,0.0002593175,0.0002509267,0.0009802288,0.00004412352,0.00248626],"genre_scores_gemma":[0.9939687,0.001593049,0.0003830004,0.0005771175,0.000239552,0.0002742588,0.001019908,0.000009358727,0.001934919],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003566272,"threshold_uncertainty_score":0.01193035,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07592762772387579,"score_gpt":0.355455073305225,"score_spread":0.2795274455813492,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}